Lifestyle and Medical Options When Facing Low eGFR Blood Test Results
An eGFR (estimated glomerular filtration rate) reported as low on a blood test can be worrying. eGFR is a calculated number that estimates how well the kidneys are filtering waste from the blood; a persistently low value may indicate chronic kidney disease (CKD) or other problems that deserve attention. This article explains what a low eGFR result means, the common medical and lifestyle options to consider, and practical steps you can take now to protect kidney health. This content is informational and not a substitute for professional medical advice—always discuss test results and treatment choices with your healthcare provider.
Why eGFR matters and how results are interpreted
eGFR is derived from a blood creatinine test combined with age, sex, and body size to estimate filtration rate in milliliters per minute per 1.73 m2. Clinicians use eGFR to screen for and stage CKD; for example, values under 60 mL/min/1.73 m2 for three months or more typically indicate CKD, while lower ranges mark more advanced stages. eGFR normally declines with age, so an isolated low value in an older adult does not always mean progressive disease—repeat testing and a urine albumin test (uACR) are commonly used to confirm whether kidney damage is chronic or transient.
Common causes and contributing factors for a low eGFR
A low eGFR can result from chronic conditions that damage the kidneys over time—most commonly diabetes and high blood pressure. Other contributors include reduced blood flow to the kidneys (from dehydration, heart failure, or vascular disease), certain medications (including some nonsteroidal anti-inflammatory drugs and higher-dose over-the-counter pain medicines), urinary tract obstruction, and intrinsic kidney diseases such as glomerulonephritis. Acute kidney injury (AKI) from severe illness or dehydration can also lower eGFR temporarily; distinguishing AKI from chronic decline is an important early step in management.
Key medical options: monitoring, medications, and specialist care
When eGFR is low, clinicians usually repeat the blood test and add a urine albumin-to-creatinine ratio (uACR) to assess protein loss, which helps determine risk and stage. For many people, controlling blood pressure and blood glucose is the first-line medical approach. Renin–angiotensin system inhibitors (ACE inhibitors or ARBs) are commonly used to reduce proteinuria and slow CKD progression when appropriate. In recent years, sodium–glucose co-transporter-2 (SGLT2) inhibitors have emerged as a kidney-protective class of medications for people with CKD, with or without diabetes, and are now part of standard care discussions for eligible patients. In more advanced stages, nephrology referral is recommended so that planning for renal replacement therapy (dialysis or transplant) or other interventions can begin in a timely way.
Lifestyle changes that support kidney function
Lifestyle adjustments can complement medical care and are often recommended regardless of CKD stage. Key measures include keeping blood pressure and blood sugar within target ranges, stopping smoking, staying physically active (for most adults, about 150 minutes of moderate activity per week), and moderating alcohol intake. Dietary changes often focus on reducing excess sodium, limiting highly processed foods, and working with a clinician or renal dietitian to adjust protein, potassium, or phosphate intake when required by lab values or symptoms. Avoiding non-essential NSAIDs and checking with a clinician before taking supplements or over-the-counter drugs are important precautions.
Benefits and considerations of treatment choices
Medical treatments and lifestyle changes can slow CKD progression and reduce cardiovascular risk, which is elevated in people with reduced kidney function. ACE inhibitors/ARBs and, where indicated, SGLT2 inhibitors have evidence showing reduced decline in eGFR and fewer major kidney events in many patients; however, these medications require monitoring for side effects such as changes in potassium and creatinine. Decisions about medication depend on individual risk factors, coexisting conditions, and lab monitoring—shared decision-making with your healthcare team is essential. For older adults with mildly reduced eGFR, the expected age-related decline may not need the same interventions as younger people with rapidly falling eGFR.
Trends and innovations in kidney care
Recent advances include wider use of SGLT2 inhibitors for kidney protection, expanded evidence for newer agents (for example, nonsteroidal mineralocorticoid receptor antagonists in select patients), and updates to how eGFR is calculated to remove race-based adjustments and reduce potential bias. Telemedicine and multidisciplinary CKD clinics have become more common, improving access to nephrology input and coordinated care such as dietary counseling, medication review, and timely planning for advanced therapies. Clinical trials continue to test therapies that may further slow progression or reduce cardiovascular complications associated with low eGFR.
Practical steps to take after receiving a low eGFR result
1) Don’t panic—ask for repeat testing and a urine albumin (uACR) to confirm chronicity and risk. 2) Review current medications with your clinician or pharmacist; stop or adjust drugs that may harm kidneys only under medical guidance. 3) Work on measurable targets: blood pressure control (individual targets depend on your health profile) and diabetes management if applicable. 4) Adopt kidney-friendly lifestyle habits—reduce sodium, maintain physical activity, avoid tobacco, and discuss protein, potassium, and phosphate with a renal dietitian if needed. 5) If your eGFR is below a threshold or declining quickly, request a nephrology referral to plan monitoring, consider therapies, and discuss when specialist interventions would be appropriate.
Table: eGFR ranges and typical clinical implications
| eGFR (mL/min/1.73 m2) | Typical classification | Usual clinical focus |
|---|---|---|
| ≥90 | Normal (if no other signs of kidney damage) | Routine monitoring; manage risk factors |
| 60–89 | Possible mild decrease (stage 2 if other damage present) | Assess for albuminuria; control BP and glucose |
| 30–59 | Moderate (stage 3) | More frequent monitoring; medication review; lifestyle changes |
| 15–29 | Severe (stage 4) | Nephrology care; prepare for potential renal replacement |
| <15 | Kidney failure (stage 5) | Dialysis or transplant planning and specialist care |
When to seek urgent or specialist care
Contact your healthcare provider promptly if you have a rapid decline in eGFR, symptoms such as significant swelling, shortness of breath, reduced urine output, persistent nausea, or if lab tests show dangerous electrolyte abnormalities. Arrange a nephrology consult if eGFR is consistently below thresholds used by your clinic or if your eGFR is falling quickly; earlier specialist involvement improves planning and outcomes. For most people with mildly reduced eGFR, primary care teams can manage monitoring and risk-factor control with guidance from nephrology when needed.
Summary and next steps
A low eGFR result signals the need for thoughtful evaluation rather than an automatic worst-case outcome. Confirmatory testing (repeat eGFR and urine albumin), medication review, risk-factor control, and individualized lifestyle adjustments are the first priorities. Medical therapies—including blood-pressure medications, SGLT2 inhibitors where appropriate, and newer agents in select cases—can slow progression for many people. Work with your healthcare team to interpret results in context, set realistic goals, and plan follow-up or referral as indicated.
Frequently asked questions
- Q: Does a single low eGFR mean I have kidney disease?
A: Not necessarily. CKD is usually diagnosed when eGFR is below 60 mL/min/1.73 m2 for three months or more or when there are signs of kidney damage such as albuminuria. Your clinician will typically repeat tests and order urine studies to determine whether the change is persistent.
- Q: Can lifestyle changes improve eGFR?
A: Lifestyle changes—blood pressure and blood sugar control, smoking cessation, healthy diet, and appropriate physical activity—can slow further decline and reduce cardiovascular risk. In many cases they complement medical treatments but may not fully reverse established loss of filtration.
- Q: Are there medicines that protect the kidneys?
A: Yes. ACE inhibitors or ARBs are commonly used to reduce protein loss and slow progression in certain patients. SGLT2 inhibitors have been shown to slow CKD progression in many patients with and without diabetes. Medication suitability depends on individual health factors and requires monitoring.
- Q: When should I see a kidney specialist?
A: See a nephrologist if your eGFR is steadily declining, is in the more advanced ranges (for example, below 30 mL/min/1.73 m2), if you have heavy albuminuria, difficult-to-control blood pressure, or complex medical issues that affect kidney care. Your primary care clinician can advise on timing.
Sources
- National Kidney Foundation — eGFR and kidney disease stages — overview of eGFR interpretation and recommended follow-up.
- NHS — Prevention and lifestyle guidance for kidney disease — practical lifestyle recommendations relevant to people with low eGFR.
- DAPA-CKD trial (dapagliflozin) — PubMed / NEJM summary — randomized evidence that SGLT2 inhibitors can slow kidney disease progression in many patients.
- Cleveland Clinic — eGFR test and results — helpful context on normal ranges and age-related changes.
If you have specific test numbers or a timeline of results and would like help understanding what they could mean, you can share those details and I can outline likely next questions to bring to your healthcare team.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
